Table 2. Retrospective study of TACE combined with immunotherapy.
| Experimental arms | Stage | Endpoints and outcomes | Ref. |
| TACE, transcatheter arterial chemoembolization; SBRT, stereotactic body radiationtherapy; PD-(L)1, programmed death-(ligand)1; MTT, molecular targeted therapies; BCLC, Barcelona Clinic Liver Cancer; uHCC, unresectable hepatocellular carcinoma; OS, overall survival; PFS, progression-free survival; ORR, objective response rate. | |||
| TACE+camrelizumab vs. TACE | HCC | 1-year PFS: 73.3% vs. 46.7% (P=0.027) | (144) |
| TACE+lenvatinib+sintilimab vs. TACE+lenvatinib | BCLC-C, uHCC | OS: 16.9 vs. 12.1 months (P=0.009); PFS: 7.3 vs.
4.0 months (P=0.002) |
(175) |
| TACE+sorafenib+nivolumab/pembrolizumab vs. TACE+sorafenib | BCLC-B/C, uHCC | PFS: 16.26 vs. 7.30 months (P<0.001); OS: 23.3 vs.
13.8 months (P=0.012) |
(176) |
| TACE+SBRT+toripalimab/sintilimab vs. TACE+toripalimab/sintilimab | BCLC-B | PFS: 19.6 vs. 10.1 months (P<0.001) | (177) |
| TACE+sorafenib+sintilimab/camrelizumab vs. TACE+sorafenib | BCLC-C | PFS: 7.63 vs. 2.9 months (P=0.0335), OS: 21.63 vs. 16.43 months (P=0.103) | (178) |
| TACE+lenvatinib+pembrolizumab/toripalimab vs. TACE+lenvatinib | uHCC | ORR: 67.9% vs. 29.6% (P<0.001); PFS: 11.9 vs. 6.9 months (P=0.003) |
(179) |
| TACE+lenvatinib+sintilimab/toripalimab vs. TACE+lenvatinib | BCLC-B | PFS: 22.5 vs. 14.0 months (P<0.001) | (180) |
| TACE+nivolumab vs. nivolumab | HCC | PFS: 8.8 vs. 3.7 months (P<0.01) | (146) |
| TACE+sorafenib+camrelizumab vs. TACE+sorafenib | BCLC-C | PFS: 6.9 vs. 3.8 months (P=0.003) | (181) |
| TACE+lenvatinib+sintilimab/camrelizumab vs. TACE+lenvatinib | BCLC-B/C, uHCC | 2 years OS rate: 74.1% vs. 43.4% (P=0.18) | (182) |
| TACE+apatinib+camrelizumab vs. TACE+apatinib | BCLC-B/C | OS: 25.5 vs. 18.5 months (P<0.01); PFS: 14.0 vs. 5.0 months (P<0.01) |
(183) |
| TACE+lenvatinib+sintilimab/camrelizumab vs. TACE+lenvatinib | BCLC-B/C | PFS: 15.4 vs. 7.8 months (P=0.005); OS: 23.1 vs. 12.5 months (P=0.004) |
(184) |
| TACE+apatinib+sintilimab vs. TACE+apatinib | HCC with MTT | PFS: 6.5 vs. 5.1 months (P<0.001); OS: 16.1 vs. 10.5 months (P<0.001) |
(185) |
| TACE+PD-(L)1+MTT vs. TACE | BCLC-B/C | PFS: 9.5 vs. 8.0 months (P=0.002) | (12) |